INTRODUCTION
Many oncologists will encounter patients whose tumors display benign histology and invasive or malignant behavior. This is particularly relevant as new pathologic entities emerge due to novel discoveries in the field, advances in molecular diagnostics, and tumor reclassifications. One example of a benign entity that can occasionally exhibit aggressive behavior is lymphangiomatosis, a rare disorder of the lymphatic system characterized by the abnormal proliferation of lymphatic vessels, sometimes referred to as generalized lymphatic anomaly. When focal these malformations are termed lymphangiomas, but when widespread the process is referred to as lymphangiomatosis [1] [2] [3] [4] [5] . This disorder is histologically benign, as organs are replaced by structurally normal lymphatic channels and cellular components are mature and well differentiated [3] .
Lymphangiomatosis is generally a disease of childhood, with most cases being diagnosed by the second decade of life [2] [3] [4] [5] .
In adults, the majority of cases of lymphangiomatosis are asymptomatic and often found incidentally on imaging ordered for unrelated conditions. Symptomatic disease, while rare, does occur and tends to be caused by compressive effects or organomegaly and the resulting sequelae [4, 5] . However, lymphatic overgrowth can cause substantial morbidity, and occasionally mortality, through local tissue destruction. Historically lymphangiomatosis has been shown to cause pulmonary, splenic or skeletal disease, though it has also been found in locations such as the intestine, extremities, head and neck, and heart [2] [3] [4] [5] . [5] . These approaches make scientific sense given the off-target antiangiogenic effects of mTOR inhibitors by way of inhibition of kinase activity resulting in cell death, and the role of VEGF in lymphangiogenesis, which is primarily driven by the interaction of VEGF-C and D isoform signaling through VEGF-receptors 2 and 3, and also by the VEGF-A isoform through VEGF receptor 2 [1] . Here, we present a case of lymphangiomatosis with multi-organ system involvement in an adult with growing lesions that was treated with pazopanib, an orally available potent and selective small molecule tyrosine kinase inhibitor targeting VEGFR 1-3, platelet-derived growth factor receptors (PDGFR) a/b, and c-kit [16] .
CASE REPORT
The patient was agreeable to having her images could not be excluded [17, 18] . At that time, it was felt a second biopsy should be obtained to further characterize the lesions outside the liver, and since several weeks had passed, repeat imaging was ordered to re-assess their behavior. The patient was again seen in follow-up and the repeat CT of the chest, abdomen and pelvis was obtained which showed further increase in the size of the hepatic lesions, growth of the spleen from 11.5 to 13.6 cm in greatest dimension and increased central hypodensity 
DISCUSSION
As clinicians, questions of monitoring and treatment are raised by cases of ''malignant masqueraders'' such as the one above. Indeed, the presentation of lymphangiomatosis with multi-organ involvement has been mistaken for advanced, metastatic cancers such as melanoma [4] 
CONCLUSION
The authors report above a case of an adult with lymphangiomatosis involving multiple organs treated with pazopanib with suggestion of clinical benefit. In the face of this mysterious, usually benign disease process which may rarely exhibit aggressive behavior, the authors encourage reports of additional cases to add to the scant literature on this subject and assist in future diagnostic and therapeutic dilemmas.
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